Regimens for the Hepatitis C Treatment-Naive Patient

Walid S Ayoub; Tram T Tran

doi:10.1016/j.cld.2015.06.003

Regimens for the Hepatitis C Treatment-Naive Patient

Clin Liver Dis. 2015 Nov;19(4):619-27, v. doi: 10.1016/j.cld.2015.06.003. Epub 2015 Aug 7.

Authors

Walid S Ayoub¹, Tram T Tran²

Affiliations

¹ Department of Gastroenterology, Cedars Sinai Medical Center, 8730 Alden Drive, Suite E235, Los Angeles, CA 90048, USA; Liver Transplant Program, Cedars Sinai Medical Center, 8900 Beverly Boulevard, Suite 250, Los Angeles, CA 90048, USA. Electronic address: Walid.Ayoub@cshs.org.
² Liver Transplant Program, Cedars Sinai Medical Center, 8900 Beverly Boulevard, Suite 250, Los Angeles, CA 90048, USA.

PMID: 26466651
DOI: 10.1016/j.cld.2015.06.003

Abstract

Hepatitis C virus (HCV) infection is a leading cause of cirrhosis and hepatocellular carcinoma, globally. Most individuals infected with HCV are asymptomatic. The introduction of the newer direct-acting antiviral (DAA) therapies has led to achievement of treatment success rates of more than 90%. Sustained virologic response is the end point of therapy, and is considered a virologic cure. It is defined as undetectable HCV RNA 12 weeks after end of therapy. This article reviews current approved non-interferon-based therapy and data from clinical trials in treatment-naive patients with chronic HCV infection.

Keywords: Cirrhosis; DAA; Direct acting antivirals; Interferon-free; Treatment naive.

Publication types

Review

MeSH terms

Antiviral Agents / therapeutic use*
Drug Therapy, Combination
Genotype
Hepacivirus / drug effects*
Hepacivirus / genetics
Hepatitis C, Chronic / drug therapy*
Humans
Nucleic Acid Synthesis Inhibitors / therapeutic use*
Protease Inhibitors / therapeutic use
RNA, Viral / biosynthesis
Viral Nonstructural Proteins / antagonists & inhibitors

Substances

Antiviral Agents
Nucleic Acid Synthesis Inhibitors
Protease Inhibitors
RNA, Viral
Viral Nonstructural Proteins
NS-5 protein, hepatitis C virus